Suppr超能文献

骨肉瘤脑转移。一名长期存活者的报告及对圣裘德儿童研究医院经验的回顾。

Brain metastases in osteosarcoma. Report of a long-term survivor and review of the St. Jude Children's Research Hospital experience.

作者信息

Marina N M, Pratt C B, Shema S J, Brooks T, Rao B, Meyer W H

机构信息

Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101-0318.

出版信息

Cancer. 1993 Jun 1;71(11):3656-60. doi: 10.1002/1097-0142(19930601)71:11<3656::aid-cncr2820711130>3.0.co;2-l.

Abstract

BACKGROUND

Brain metastasis has been considered a rare event in osteosarcoma, although with prolonged survival an increasing incidence has been suggested. There have been no prior reports of long-term survivors among patients with this complication.

METHODS

The authors describe a child treated for osteosarcoma who is alive and free of disease 8 years after the detection of brain metastases. Of 254 patients with primary osteosarcoma referred to St. Jude Children's Hospital between 1962 and 1989, 13 developed brain metastases, all after relapse or recurrence in another site. Concomitant active lung metastases were present in all of the patients except the one long-term survivor, whose pulmonary disease had responded to treatment with cisplatin and doxorubicin. Log-rank analyses were used to compare survival duration and the frequency of brain metastases among patients treated before and after 1982, when effective multiagent therapy was initiated.

RESULTS

Log-rank analyses comparing patients treated before and after 1982 showed that the introduction of effective modern therapy improved survival among patients at risk for brain metastases (i.e., those with recurrent and progressive disease, P = 0.007) but was not associated with a statistically significant increase in the frequency of brain metastases (15.5% versus 4.5%, P = 0.125).

CONCLUSIONS

Although the outlook for patients with this complication remains bleak, the resolution of brain metastases after eight courses of ifosfamide in the patient described in this article suggests that enrollment of selected patients in Phase II trials is merited.

摘要

背景

脑转移瘤在骨肉瘤中一直被认为是罕见事件,尽管随着生存期延长,其发病率有上升趋势。此前尚无关于该并发症患者长期存活的报道。

方法

作者描述了一名骨肉瘤患儿,在检测到脑转移瘤后8年仍存活且无疾病迹象。在1962年至1989年间转诊至圣裘德儿童研究医院的254例原发性骨肉瘤患者中,13例发生了脑转移瘤,均在其他部位复发后出现。除了这名长期存活者外,所有患者均伴有活动性肺转移,该患者的肺部疾病对顺铂和阿霉素治疗有反应。采用对数秩检验分析比较1982年有效多药联合治疗开始前后接受治疗的患者的生存期和脑转移瘤发生率。

结果

对数秩检验分析比较1982年前后接受治疗的患者,结果显示有效现代治疗方法的引入改善了有脑转移瘤风险患者(即复发和进展性疾病患者)的生存期(P = 0.007),但与脑转移瘤发生率的统计学显著增加无关(15.5%对4.5%,P = 0.125)。

结论

尽管该并发症患者的预后仍然不佳,但本文所述患者在接受八个疗程异环磷酰胺治疗后脑转移瘤得到缓解,这表明值得将部分患者纳入II期试验。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验